Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer by Barrow TM et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Barrow TM, Barault L, Ellsworth RE, Harris HR, Binder AM, Valente AL, Shriver 
CD, Michels KB.Aberrant methylation of imprinted genes is associated with 
negative hormone receptor status in invasive breast cancer. International 
Journal of Cancer 2015, 137(3), 537-547. 
 
Copyright: 
This is the peer reviewed version of the following article: Barrow TM, Barault L, Ellsworth RE, Harris HR, 
Binder AM, Valente AL, Shriver CD, Michels KB.Aberrant methylation of imprinted genes is associated 
with negative hormone receptor status in invasive breast cancer. International Journal of 
Cancer 2015, 137(3), 537-547, which has been published in final form at 
http://dx.doi.org/10.1002/ijc.29419. This article may be used for non-commercial purposes in accordance 
with Wiley Terms and Conditions for Self-Archiving. 
 
DOI link to article: 
http://dx.doi.org/10.1002/ijc.29419 
Date deposited:   
26/01/2016 
Embargo release date: 
21 January 2016  
 1 
Aberrant methylation of imprinted genes is associated with 
negative hormone receptor status in invasive breast cancer 
 
Timothy M Barrow†1,2, Ludovic Barault†1#, Rachel E Ellsworth3, Holly R Harris1, 
Alexandra M Binder1, Allyson L Valente4, Craig D Shriver5, Karin B Michels*1,2. 
 
†These authors contributed equally to the work 
1Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics, 
Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA 02115, U.S.A.. 
2Instiut für Prävention und Tumorepidemiologie, Universitätsklinikum Freiburg, 79106 
Freiburg, Germany. 
3Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of 
Military Medicine, Windber, PA 15963, U.S.A.. 
4Clinical Breast Care Project, Windber Research Institute, Windber, PA 15963, 
U.S.A.. 
5Clinical Breast Care Project, Walter Reed National Military Medical Center, 
Bethesda, MD 20889, U.S.A.. 
#Current address: IRCC Institute for Cancer Research and Treatment at Candiolo, 
10060 Candiolo (Torino), Italy. 
 
*To whom correspondence should be addressed: Tel: +1 617 7324895. Fax: +1 617 
7324899.  Email: kmichels@research.bwh.harvard.edu  
Short title: Imprinting and receptor status in breast cancer. 
 
Article category: Cancer Genetics 
 2 
 
Impact: This is the first study, to our knowledge, to identify an association between 
the aberrant DNA methylation of imprinted genes and negative status of the estrogen 
and progesterone receptors in breast cancer.  Furthermore, we describe how 
variation in methylation of these genes increases from normal breast tissue to benign 
breast disease to cancer.  Our findings may imply an important role for epigenetic 
disruption of imprinted genes in the development of different breast cancer subtypes. 
 
Keywords: DNA methylation; genomic imprinting; pyrosequencing; breast cancer; 
hormone receptor. 
 
Abbreviations: CBCP: Clinical Breast Care Project; CpG: cytosine-phosphate-
guanine; DMR: differentially methylated region; ER: estrogen receptor; FAM: 
frequently altered methylation; FISH: fluorescence in situ hybridization; HER2: 
human epidermal growth factor receptor 2; ICR: imprinting control region; LOI: loss of 
imprinting; PR: progesterone receptor. 
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Abstract 
Epigenetic regulation of imprinted genes enables monoallelic expression according to 
parental origin, and its disruption is implicated in many cancers and developmental 
disorders.  The expression of hormone receptors is significant in breast cancer as 
they are indicators of cancer cell growth rate and determine response to endocrine 
therapies.  We investigated the frequency of aberrant events and variation in DNA 
methylation at nine imprinted sites in invasive breast cancer and examined the 
association with estrogen and progesterone receptor status.  Breast tissue and blood 
from patients with invasive breast cancer (n=38) and benign breast disease (n=30) 
were compared to those from healthy individuals (n=36), matched to the cancer 
patients by age at diagnosis, ethnicity, BMI, menopausal status, and familial history 
of cancer.  DNA methylation and allele-specific expression were analyzed by 
pyrosequencing.  Tumor-specific methylation changes at IGF2 DMR2 were observed 
in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 
23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8%, and 
SNRPN/SNURF ICR in 4%.  Variation of methylation was significantly greater in 
breast tissue from cancer patients than healthy individuals and benign breast 
disease.  Aberrant methylation of three or more sites was significantly associated 
with negative estrogen-alpha (Fisher’s Exact Test, p=0.02) and progesterone-A 
(p=0.02) receptor status.  Aberrant events and increased variation of imprinted gene 
DNA methylation therefore appear to be frequent in invasive breast cancer and are 
associated with negative estrogen and progesterone receptor status, without loss of 
monoallelic expression.
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Introduction 
Genomic imprinting is the epigenetic regulation of genes to enable monoallelic 
expression according to parental origin, through differential methylation of regions 
labeled imprinting control regions (ICRs) when established in the germline, or 
differentially methylated regions (DMRs) when established post-fertilization.  Loss of 
imprinting (LOI) is the loss of this monoallelic expression, and it is commonly the 
result of disruption of DNA methylation at ICRs and DMRs.  LOI is associated with a 
range of disorders, such as the Beckwith-Wiedemann, Angelman and Prader-Willi 
syndromes1,2.  Imprinted genes have also been implicated in a range of cancers, 
including those of the breast3 and ovaries4.  Their expression has been associated 
with disease progression, including reduced survival in pancreatic cancer5 and 
aggressive prostate cancers6.  Aberrant methylation of imprinted genes may be an 
early event involved in neoplastic transformation7, and it has been reported that 10% 
of apparently healthy individuals display LOI of IGF28. 
 DNA methylation can display stochastic variation, which may facilitate 
developmental plasticity and adaptation to environments, including that of malignant 
cells in the tumor microenvironment9.  This variation can be gene-specific, such as 
that as observed in the placenta to enable adaptation to environmental challenges 
throughout pregnancy10.  A significantly greater level of variation is observed in 
tumors, which often constitutes shifting in methylation ‘boundaries’ between CpG 
islands and shores11.  Such events may occur early in tumorigenesis, demonstrated 
by the significantly increased variation observed in cervical cells of normal 
morphology12. 
Breast cancers are classified according to the expression of the estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2).  ER-alpha and PR-A expression are determined by 
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immunohistochemistry, with tumors in which more than 5-10% of cells stain positively 
classified as positive for expression. HER2 expression is determined by 
immunohistochemistry, with scores of 0-3 according to intensity of staining, and by 
fluorescence in situ hybridization (FISH) to detect amplification of the gene.  
Activation of these receptor signaling pathways results in cellular proliferation, and 
they are implicated in the progression of breast and gynecological cancers.  
Approximately two-thirds of tumors display expression of at least one of the hormone 
receptors, and these patients display reduced mortality compared to those who 
express neither13, in part due to the efficacy of endocrine therapies.  Triple-negative 
breast cancers, which account for approximately 12-17% of all cases14, are 
associated with poor prognosis. 
The relation between imprinted genes and hormone receptor status in breast 
cancer has not been well elucidated.  Correlations between the methylation of four 
tumor-suppressor genes and the expression of the hormone receptors has been 
observed3, but similar studies have not been performed for imprinted genes.  
Elucidating such a relationship may provide insight into tumorigenesis and the 
determination of prognostic factors. 
In this study, we investigated the aberrant methylation of nine imprinted 
regions in samples of breast tissue taken from healthy individuals and patients with 
benign breast disease and invasive breast cancer.  The interrogated imprinted 
regions were: DIRAS3 DMR; GRB10 ICR; H19 ICR; IGF2 DMR0 and DMR2; 
KvDMR; MEST ICR; PEG3 DMR; and SNPRN/SNURF ICR.  The intra-individual 
tissue-specificity of the aberrant methylation events was determined by comparison 
of methylation in DNA from breast tissue and peripheral blood within individuals.   
Variation of DNA methylation in imprinted genes and LINE-1 global methylation were 
measured, and possible associations between aberrant methylation and the status of 
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the estrogen, progesterone and HER2 receptors in breast cancer patients were 
identified.  Finally, we analyzed the allele-specific expression of the genes in order to 
establish the relative impact of the aberrant methylation events. 
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Materials and methods 
Study populations 
The Clinical Breast Care Project (CBCP) is a clinical and research program that 
began enrolling patients in 2001. The primary clinical arm of the CBCP was the 
Clinical Breast Care Center at Walter Reed Army Medical Center (Washington DC, 
USA). Additional recruitment centers include the Joyce Murtha Breast Care Center 
(Windber, PA, USA), and the Anne Arundel Medical Center (Annapolis, MD, USA).  
Enrolled patients were required to be 18-years-old or older, mentally competent and 
willing to provide informed consent, and presenting with evidence of possible breast 
disease, attending for routine screening mammograms, or undergoing elective 
reductive mammoplasty. Patients were provided with layered consent forms that 
included permission to obtain samples of blood, breast and metastatic tissues, and a 
description of the primary research uses. Once informed consent was granted, the 
core questionnaire, with over 500 fields of information, was completed with the help 
of a nurse case manager, and an extensive pathology checklist was completed by 
the dedicated breast pathologist.  Ethical approval for the collection of blood and 
tissue samples and their use in this study was provided by the Walter Reed Army 
Medical Center Human Use Committee and Institutional Review Board. 
 The Susan G. Komen for the Cure Tissue Bank (Indianapolis, IN, USA) is a 
charitable organization that enrolls healthy volunteers to donate blood and up to four 
breast biopsies.  Eligible individuals must be at least 18 years of age and able to 
provide informed consent.  Volunteers are asked to complete a questionnaire 
regarding health and lifestyle factors.  Approval for the collection of blood and tissue, 
and for their use in this study, was provided by the Indiana University Institutional 
Review Board.   
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Blood and tissue samples 
DNA and RNA from benign and tumor tissue and blood were obtained from the 
CBCP for 38 patients with invasive breast cancer and 30 with benign breast disease 
(13 fibrocystic changes, 8 fibroadenoma, 3 post-surgical changes, 2 stromal fibrosis, 
and 4 other) (Table 1, Supplementary Table 1).  Genomic DNA was extracted from 
frozen tumor samples following laser microdissection (Leica Microsystems, Wetzlar, 
Germany) and homogenized benign tissue by incubation with proteinase K at 37oC 
overnight and passage through purification columns (Millipore, Billerica, MA, USA).  
DNA extractions from blood were performed using Clotspin and Puregene DNA 
purification kits (Qiagen, Valencia, CA, USA) according to the manufacturer’s 
instructions. 
Samples from 36 healthy individuals were obtained from the Susan G. Komen 
for the Cure Foundation Tissue Bank (Table 1).  DNA was extracted from 25mg 
tissue using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s 
protocol, following proteinase K digestion at 56oC for 3-6 hours.  RNA extractions 
were performed using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
protocol, following mechanical disruption of 25mg tissue in a bead mill.  Between 2 
and 41μg of DNA isolated from blood was made available for this study. 
 
Bisulfite conversion of DNA 
250–500ng of DNA was converted using the EZ DNA Methylation Gold kit (Zymo 
Research, Irvine, CA, USA), according to the manufacturer’s Alternative 2 protocol, 
with elution in 40μl of elution buffer.  
 
DNA methylation analysis by pyrosequencing 
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Pyrosequencing was performed on the Pyromark Q24 Pyrosequencer (Qiagen).  
Assays were designed using the PyroMark Assay Design and PyroMark Q24 
software programs (Qiagen), with the exceptions of those for H19 ICR, IGF2 DMR0 
and IGF2 DMR2, which have previously been reported15-17.  Nine DMRs/ICRs were 
analyzed: DIRAS3 DMR (5 CpG dinucleotides); GRB10 ICR (6 CpGs); H19 ICR (8 
CpGs); IGF2 DMR0 (6 CpGs); IGF2 DMR2 (7 CpGs); KvDMR (9 CpGs); MEST ICR 
(9 CpGs) PEG3 DMR (6 CpGs); and SNRPN/SNURF ICR (8 CpGs) (Supplementary 
Table 2).  
Regions of interest were amplified by polymerase chain reaction (PCR), using 
3μl of bisulfite-treated DNA and 0.2μM of each primer with HotStar Taq Plus Master 
Mix (Qiagen) in a final volume of 20μl.  Pyrosequencing was performed according to 
the manufacturer’s instructions.  Duplicate bisulfite-conversions were run for each 
sample and mean methylation levels were calculated across all CpG sites per 
replicate.    Studies in healthy human tissues have reported methylation levels of 
between 30 and 70% at DMRs and ICRs16,17, and we therefore defined 
hypomethylation as values below 30% and hypermethylation as values above 70%.  
It was not possible to ascertain methylation values for all samples. 
 
Identification of allelic origins of mRNA 
Allele-specific expression was performed by pyrosequencing, using single nucleotide 
polymorphisms (SNPs) to determine the allelic origins of mRNA transcripts in 
heterozygous patients, identified by pyrosequencing using 10ng of DNA from blood.  
For heterozygous individuals, 20ng of RNA was reverse-transcribed using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Hercules, USA) according to the 
manufacturer’s instructions, and 2μl of cDNA used for PCR-based amplification prior 
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to allele quantification by pyrosequencing.  Primer sequences and SNPs are 
provided in Supplementary Table 2. 
 
Gene expression microarray data 
Expression data for ten genes (DIRAS3, DNMT1, DNMT3A, DNMT3B, GRB10, IGF2, 
KCNQ1, MEST, PEG3, and SNRPN) from 302 breast tumors were made available by 
the Walter Reed Army Medical Center (Washington DC, USA).  Of the tumors, 199 
were ER-positive and 103 were ER-negative, and 153 were PR-positive and 149 PR-
negative. 
 
Statistical analysis 
Correlations between DNA methylation and age at diagnosis were calculated by 
Pearson correlation for all genes except GRB10, for which Spearman’s rank 
correlation was used as the data was not normally distributed.  Associations with 
tumor stage, receptor status and familial history of cancer were calculated by 
ANOVA.  For the FAM group, associations were calculated by Fisher’s exact test, 
and associations with age at diagnosis calculated by t-test or Wilcoxon rank sum test, 
according to the distribution of the data.  P values below 0.05 were deemed 
statistically significant. 
For the modeling of variation, deviation was calculated as the absolute 
difference between the median methylation level in blood or breast tissue from 
healthy individuals and the methylation level for the individual.  This was conducted 
for each gene, for comparisons of samples from patients with benign breast disease 
and cancer to the healthy controls, in both blood and breast tissue.  A general 
linearized model was used to model deviation with a gamma distribution, and a log 
link.  Model coefficients and 95% confidence intervals were exponentiated to give the 
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relative change in deviation between tissues.  The adjusted model controlled for 
family history (binary), menopausal status (binary), BMI category (normal, <25; 
overweight, 25 – 30; obese, >30), and age (continuous).  Results were corrected for 
multiple hypothesis testing using the Bonferroni correction, and p values below 0.05 
deemed statistically significant.  
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Results 
Aberrant DNA methylation of imprinted genes is a frequent event in breast tumors 
We investigated the DNA methylation at nine imprinted regions in breast tissue and 
peripheral blood from 36 healthy individuals, 30 patients with benign breast disease 
and 38 with invasive cancer.  We have previously reported methylation levels at six 
of the imprinted regions (GRB10 ICR, H19 ICR, IGF2 DMR0, IGF2 DMR2, KvDMR, 
and SNRPN/SNURF ICR) in patients with benign breast disease and breast cancer18, 
and we integrated these results with methylation levels measured in healthy 
individuals to identify the relative frequency of aberrant methylation (hypo- and 
hypermethylation) in the disease states.  
In breast tissue, median methylation levels were close to the expected 50% 
with the exception of the IGF2 sites, which also displayed greater disparities in the 
median levels between normal, benign and tumor tissue (Figure 1).  Aberrant 
methylation was frequently observed in invasive breast cancer, observed at IGF2 
DMR2 in 59% of patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 
23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8%, and 
SNRPN/SNURF ICR in 4% (Supplementary Table 3).  Hypomethylation was more 
common than hypermethylation at all sites except MEST ICR and PEG3 DMR, and 
was not associated with whether the genes are maternally or paternally expressed.  
Among patients with benign breast disease, aberrant methylation was only observed 
at IGF2 DMR2, which was hypomethylated in 12 of the 26 successfully-analyzed 
samples.  No aberrant methylation was observed in healthy individuals at seven of 
the imprinted regions, with IGF2 DMR0 hypermethylated in one sample and IGF2 
DMR2 hypomethylated in three.    
To determine the intra-individual tissue specificity of the methylation changes 
observed in breast tumors, we analyzed peripheral blood samples taken from the 
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same individuals.  Median values for all nine regions were between 39.1 and 53.6% 
across the three groups (Supplementary Table 3).  No samples met the criteria of 
being hypo- or hypermethylated, indicating that the aberrant methylation events were 
unique to breast tissue. 
 
Variation of DNA methylation is significantly greater in breast tissue and blood from 
patients with invasive breast cancer and benign breast disease 
Variation of DNA methylation in the healthy and disease states was estimated by the 
absolute difference between the methylation level in an individual and the median 
level measured in breast tissue or peripheral blood from healthy individuals, with the 
latter representing the normal value.  The mean deviation from the median 
methylation levels observed in normal breast tissue was greatest in invasive tissue, 
ranging from 6.6% for SNRPN/SNURF ICR to 23.0% for IGF2 DMR0 (Figure 2A, 
Supplementary Table 4A).  The mean deviations were lowest in normal breast tissue, 
where they were under 2.0%, with the exceptions of IGF2 DMR0 (4.2%) and IGF2 
DMR2 (5.5%).  Benign breast tissue displayed intermediate values, with median 
deviation ranging from 2.5% for DIRAS3 DMR to 11.2% for IGF2 DMR2. 
The mean deviations in healthy individuals were lower in blood than in breast 
tissue, with the exceptions of PEG3 DMR in healthy individuals and DIRAS3 DMR in 
patients with benign breast disease (Figure 2A, Supplementary Table 4A).  The 
deviations were greatest in blood from invasive breast cancer patients, where median 
deviations ranged between 1.7% and 6.6%.  The values ranged between 1.5 and 
6.7% among benign breast disease patients, and between 0.7 and 3.2% in healthy 
individuals. 
The relative deviations from the median methylation levels were significantly 
greater at all interrogated regions in tumor tissue than in normal breast tissue, 
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ranging from 2.6-fold (IGF2 DMR2) to 9.7-fold (DIRAS3 DMR) greater (Figure 2B, 
Supplementary Table 4B).  When the model was adjusted for the age, BMI, 
menopausal status and familial history of cancer of the individuals, statistical 
significance was retained at all sites.  Variation was also significantly greater in 
benign breast disease tissue than normal breast tissue for all DMRs except DIRAS3 
DMR, with the relative deviations between 1.5-fold (DIRAS3 DMR) and 7.5-fold 
(SNRPN/SNURF ICR) greater.  Significance was retained for all sites except IGF2 
DMR0 and MEST ICR with the adjusted model. 
 Significantly greater variation of methylation was similarly observed in 
peripheral blood.  Mean deviations in blood from patients with invasive breast cancer 
were between 1.3-fold (DIRAS3 DMR) and 7.4-fold (SNRPN/SNURF ICR) greater 
than in healthy individuals, and were significant for GRB10 ICR, KvDMR, PEG3 DMR 
and SNPRN/SNURF ICR.  In the adjusted model, the relative changes were 
significant for GRB10 ICR, IGF2 DMR2, PEG3 DMR and SNRPN/SNURF ICR 
(Supplementary Table 4B).  Mean deviations were also between 1.3-fold (IGF2 
DMR0) and 7.5-fold (SNRPN/SNURF ICR) greater in blood taken from patients with 
benign breast disease than in healthy individuals (Figure 2B, Supplementary Table 
4B).  The differences were significant for GRB10 ICR, MEST ICR, PEG3 DMR and 
SNRPN/SNURF ICR in both the adjusted and unadjusted models (Supplementary 
Table 4B). 
 
Aberrant DNA methylation is Associated with Hormone Receptor Status 
We investigated possible associations between the measured methylation values at 
each imprinted loci and expression of the estrogen (ER), progesterone (PR) and 
HER2 receptors (details in Supplementary Table 1). Hypermethylation of PEG3 DMR 
(ANOVA, p<0.01) and IGF2 DMR0 (p=0.04) were associated with negative ER 
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status, while hypermethylation of PEG3 DMR (p=0.02) and MEST ICR (p=0.03) were 
associated with negative PR status (Table 2).  No associations were observed 
between the methylation of imprinted genes and the expression of HER2 or tumor 
stage. 
 
Frequently altered methylation (FAM) and hormone receptor status 
Twelve of the invasive tumors analyzed displayed aberrant methylation of at least 
three of the imprinted regions that were interrogated.  We categorized these together 
as “frequently altered methylation” (FAM).  FAM was associated with negative ER 
(Fisher’s exact test, p=0.02) and PR status (p=0.02), but not HER2 (p=0.32) or tumor 
stage (p=0.15) (Table 2).  All five triple-negative tumors displayed aberrant 
methylation at three or more sites. 
Methylation at LINE-1 repetitive elements was measured in breast tissue from 
patients with benign breast disease and invasive cancer, and analyzed according to 
the FAM grouping of cancers and the expression of the estrogen receptor (Figure 3A-
B).  Greater variation was observed in breast tumors, with values ranging between 50 
and 79% compared to 69-77% in benign breast disease tissue (Figure 3A).  Within 
the tumor samples, median values were similar in the FAM (71.1%) and non-FAM 
(71.8%) groups, but slightly higher in ER-negative tumors (73.2%) than in ER-
positive ones (71.5%).  Tumors expressing the estrogen receptor also displayed a 
greater range of values (50 to 76%) in comparison to those that do not (66 to 79%) 
(Figure 3B).   
 
Monoallelic expression of imprinted genes is maintained in breast tumors 
To determine the impact of the observed methylation changes, we examined the 
allele-specific expression of the genes. Firstly, we genotyped the cancer patients for 
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SNPs in the DIRAS3, GRB10, H19, IGF2, MEST and PEG3 genes.  KCNQ1 and 
SNRPN were not analyzed due to the infrequency of aberrant methylation in the 
tumor samples.  We identified 24 patients who were heterozygous for SNPs in the 
PEG3 gene, 18 for IGF2, 14 for GRB10, 10 for H19, 7 for MEST and 4 for DIRAS3. 
Monoallelic expression, defined here as >85% of transcripts from a single 
allele, was almost exclusively retained (Figure 4).  PEG3 was monoallelically 
expressed in 17 of 18 patients with normal methylation levels and 5 of 6 patients 
displaying hypermethylation of the gene (Figure 4A).  In the other two patients, 71 
and 81% of transcripts originated from a single allele.  Monoallelic expression was 
observed in five of the seven patients informative for MEST, with 79% and 80% of 
transcripts expressed from a single allele in the other two patients (Figure 4B).    All 
18 patients informative for IGF2 monoallelically expressed the gene, including the 4 
patients with hypomethylation of DMR0 and 4 displaying hypomethylation of DMR2 
(Figures 4C-D). Monoallelic expression of H19 was observed in 8 of the 10 
informative patients, including the one displaying hypomethylation of the gene 
(Figure 4E).  Two individuals displayed biallelic expression despite normal 
methylation profiles, with the relative expression of the two alleles 64/36% and 
55/45%.  GRB10 displayed a markedly different pattern of expression, with the 
proportional expression of the two alleles between 51/49% and 60/40% in 7 of the 14 
informative patients, and only three patients expressed >70% of transcripts from a 
single allele (Figure 4F).  DIRAS3 results are not shown due to the lack of informative 
patients. 
 
GRB10 and IGF2 are differentially expressed in ER-positive tumors 
To further examine the relation between hormone receptor status and the expression 
of imprinted genes, we utilized gene expression microarray data from 302 breast 
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tumor samples, made available through the Walter Reed Army Medical Center.  
Expression of seven of the imprinted genes was analyzed between ER-positive 
(n=199) and ER-negative (n=103) tumors, and between PR-positive (n=153) and PR-
negative (n=149) tumors.  H19 expression was not covered by the array. GRB10 
expression was 1.4-fold lower (p=1.7x10-10) and IGF2 expression was 1.9-fold higher 
(p=6.0x10-7) in ER-positive tumors (Supplementary Table 5).  No significant 
differences were observed by PR status. 
 
Expression of DNA methyltransferases are not associated with hormone receptor 
status 
To investigate how DNA methylation at imprinted regions may be related to estrogen 
and progesterone receptor status, we utilized gene expression microarray data from 
302 breast tumor samples (Supplementary Table 5).  We observed no significant 
differences in the expression of the DNMT1 (-1.1 fold-change), DNMT3A (-1.3 fold-
change) and DNMT3B (-1.6 fold-change) genes in ER-positive tumors in comparison 
to ER-negative ones.  Similarly, no significant difference was observed for any of the 
three genes (-1.1, -1.1 and -1.3 fold-changes respectively) in PR-positive tumors 
versus PR-negative tumors. 
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Discussion 
We found the imprinted regions DIRAS3 DMR, GRB10 ICR, H19 ICR, IGF2 DMR0, 
IGF2 DMR2, MEST DMR and PEG3 DMR to be frequently aberrantly methylated in 
the patients with invasive breast cancer included in this study.  These alterations are 
highly tissue- and tumor-specific, with no such changes observed in blood and only 
highly infrequently in normal breast tissue and benign breast disease tissue.  This 
result confirmed our previous work in which we observed no correlation between the 
methylation at six imprinted regions in breast tumors and matched peripheral blood18.  
Variation of DNA methylation was significantly greater at all nine imprinted regions in 
breast tumors comparison to normal breast tissue, and at eight (unadjusted model) 
and six (adjusted) of the regions in benign breast disease tissue.  Aberrant 
methylation of more than three of the imprinted regions was significantly associated 
with negative status of the estrogen and progesterone receptors.  Despite this 
disruption of DNA methylation, monoallelic expression of the imprinted genes was 
frequently maintained. 
This is the first study to identify a correlation between the methylation of 
imprinted genes and expression of the estrogen and progesterone receptors in 
breast cancer.  ER-positive and ER-negative tumors have distinct global DNA 
methylation profiles19,20, and work in animal models and cell lines has demonstrated 
that hormone receptor signaling, including that by agonists such as bisphenol A, can 
affect the expression of DNA methyltransferases21-23 and directly lead to changes in 
the methylation and expression of imprinted genes such as IGF2 and PEG321,24,25.  
Furthermore, in vitro studies have shown that expression of the imprinted gene 
CDKN1C is repressed via epigenetic mechanisms induced by estrogen signaling in 
breast cancer cell lines26.  Taken together with our observations in primary human 
breast tumors, this may suggest that normal hormone receptor signaling is important 
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for the maintenance of methylation for imprinted genes, and absence of such 
signaling may result in aberrant regulation in malignant cells.  Interestingly, in vitro 
work has demonstrated that mutations in the DNMT1 gene lead to loss of IGF2 and 
PEG3 imprinting, with KCNQ1 less susceptible to such changes27, and we similarly 
observed that aberrant methylation of the IGF2 and PEG3 DMRs was substantially 
more frequent than at the KvDMR (Figure 2A), although we did not observe an 
impact upon allele-specific expression.  However, we did not observe significantly 
different expression of DNMT1, DNMT3A or DNMT3B between ER-positive and ER-
negative tumors (Supplementary Table 5).  Our findings may either suggest that the 
relation between DNA methylation at imprinted loci and ER signaling may be 
confined to a subset of ER-negative tumors, or that the association is independent of 
the regulation of DNA methyltransferase expression reported in vitro. 
Similar associations between DNA methylation and hormone receptor status 
have been identified for non-imprinted genes3,28.  However, the differential 
methylation of alleles and roles in regulating proliferation and differentiation make 
imprinted genes particularly susceptible to driving tumorigenesis.  Indeed, changes in 
the methylation of imprinted genes have been reported in esophageal dysplasia29 
and localized ovarian tumors30.  As the ER is frequently silenced by promoter 
methylation in breast tumors31, it is not clear whether hormone receptor status is the 
cause or product of wider epigenetic dysregulation.  Further work is required to 
establish whether a subset of breast tumors may display a characteristic epigenetic 
profile.  The identification of such a group may open new therapeutic options to the 
patients, including the combined use of 5-Azacytidine and S-adenosylmethionine, 
which inhibit the growth of breast cancer cells32. 
 We observed increasing variation in DNA methylation from normal breast 
tissue to benign breast disease to cancer.  This finding is consistent with 
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observations made by Teschendorff and colleagues, who suggested increased 
variability as a marker for early detection of cervical cancer, even being present in 
cytologically-normal cells of individuals who later developed12.  Thus, this variability 
may be a key part of the neoplastic transformation process.  It may arise through the 
shifting of methylation boundaries, rather than gene-specific changes11.  As we have 
employed a candidate-gene approach, with comparatively short reads obtained by 
pyrosequencing, it remains uncertain whether this variability is confined to the 
interrogated DMRs or whether it may be the result of wider boundary-shifts.  
Furthermore, the degree of variation of methylation within the tumors remains 
unknown.  Mosaicism is a well-known phenomenon in cancer, and may provide some 
explanation for our observations.”. 
Increased variability in DNA methylation has been proposed as a blood-based 
marker for ovarian cancer33, and we similarly observed significantly increased 
variation in both the adjusted and unadjusted models at GRB10 ICR, PEG3 DMR 
and SNRPN/SNURF ICR in peripheral blood from cancer patients.  However, the 
statistical significance may be the product of the tight clustering of values observed in 
healthy individuals, with mean deviations from median values below 3.5% at all sites.  
While group differences may be significant, the value for risk prediction in individuals 
remains uncertain. 
The sites displaying the most frequent aberrant methylation and greatest 
variation were the two IGF2 DMRs. IGF2 is a widely studied oncogene that 
stimulates cellular proliferation, and hypomethylation of DMR0 is associated with 
poor prognosis with colorectal cancer34.  We observed that hypomethylation of DMR0 
was associated with negative ER status, which is itself associated with poor 
prognosis in breast cancer13.  The observed frequency of hypomethylation was 
similar to that reported elsewhere16.   While loss of IGF2 imprinting in peripheral 
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blood has been suggested as a potential diagnostic marker for colorectal cancer8, 
changes in methylation at DMR0 were specific to the tumors, and we have previously 
reported a lack of correlation between blood and tumor tissues18.  This may suggest 
that peripheral blood cannot serve as a surrogate tissue, although correlations may 
be gene-specific, as there is evidence that methylation of ATM35 and targets of ER 
signaling36 could be used as blood-based markers of breast cancer risk. 
Interestingly, the disruption of methylation did not impact upon allele-specific 
expression in the tumors, with monoallelic expression almost exclusively retained.  
Conversely, our results suggest that GRB10, which is monoallelically expressed in 
fetal brain tissues and placenta but not in other fetal tissues37-39, may not be 
imprinted in breast tissue in adult humans.  Loss of IGF2 imprinting has been 
reported in colorectal and ovarian tumors8,40 and PEG3 in gynecological cell lines41, 
but we observed >77% of transcripts originating from a single allele in all the tumor 
samples informative for these genes.  Furthermore, our observation of 
monoallelically-expressed MEST in all seven informative patients is in direct contrast 
to findings elsewhere of biallelic expression in breast cancer patients42.  While H19 
was biallelically expressed in two patients, methylation of the H19 ICR was not 
disrupted in these tumors, suggesting an alternative cause of LOI.  Hypomethylation 
of H19 ICR has been correlated with LOI in lung cancer43, but there is evidence that 
the IGF2/H19 competition model does not hold true in colorectal44,45 and ovarian40 
tumors.  Similarly, a lack of correlation has been observed between hypomethylation 
of IGF2 DMR0 and LOI in colon and breast tumors16, while hypomethylation of IGF2 
DMR0 in ovarian serous tumors increases overall expression but does not result in 
biallelic expression40.  While the classical model of imprinting suggests that 
monoallelic expression is the product of differential methylation of the two alleles, this 
does not appear to hold as strongly in humans as it does in mice.  However, it is not 
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clear why the frequency of LOI is lower here than reported elsewhere, as this 
phenomenon has been reported in primary breast tumors42,46.  An alternative 
explanation for our observations could be that the changes in DNA methylation are 
confined to a subset of cells in which expression is silenced.  As pyrosequencing 
enables the measurement of the relative abundance of the transcripts from the two 
alleles, but not their overall quantity, our observations of monoallelic expression 
being retained may be based upon an inability to detect silencing of the expressed 
allele in the affected cells. 
There have been few studies investigating epigenetic dysregulation in benign 
breast disease.  Although proliferative benign disease is associated with a greater 
relative risk of developing cancer47, we have previously reported no significant 
difference in methylation at six of the imprinted loci between proliferative and non-
proliferative conditions18.  There is limited evidence of loss of IGF2 imprinting in 
benign breast disease48, and we observed that hypomethylation of IGF2 DMR2 was 
highly frequent.  Although aberrant methylation was not observed at the other 
regions, there was significantly greater variability in methylation at six (adjusted 
model) and eight (unadjusted) sites, and increased variability in cytologically-normal 
epithelial cells is associated with increased risk of developing neoplasia12.  Further 
work is required to establish the possible role of epigenetic dysregulation in the 
etiology of benign breast disease. 
A limitation of our study is the potential difference in the proportions of cell 
types between the normal, benign and tumor tissues.  Laser-microdissection of the 
tumor tissue was performed to isolate malignant cells, but was not conducted with 
normal tissue to enrich the epithelial cells.  While median DNA methylation values in 
normal tissue were consistently close to the expected 50% value, we cannot rule out 
that the variation modeling may have been affected.  We also cannot exclude the 
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possibility of copy number changes influencing measured methylation values in the 
samples, as insufficient quantities of DNA remained following epigenetic analyses to 
also perform genetic analyses.  Furthermore, the number of samples in this study 
may also have precluded us from identifying other significant correlations between 
DNA methylation and tumor subtype, such as with triple-negative tumors.  A 
particular strength of this study is the access to breast tissue from healthy individuals.  
There is evidence that histologically-normal tissue adjacent to breast tumors can 
possess genomic alterations seen in the cancer49, and therefore it is important to use 
breast tissue from healthy women as controls in order to accurately identify changes 
associated with malignant transformation. A further strength was the availability of 
both DNA and RNA from blood and breast tissue that has enabled us to investigate 
the specificity of changes in DNA methylation and the effect upon allele-specific 
expression. 
This is the first study, to our knowledge, to identify an association between the 
aberrant methylation of imprinted genes and hormone receptor status in breast 
cancer.  We have established that 1) aberrant events in the DNA methylation of 
these imprinted regions are frequent in breast tumors, 2) variation is greater in both 
breast tissue and in blood from patients with invasive breast cancer than in healthy 
individuals, and 3) aberrant changes in DNA methylation are associated with 
hormone receptor status in the tumors.  Further work is required to establish whether 
such methylation changes are the direct result of loss of hormone receptor signaling 
or are the product of more widespread changes in global DNA methylation. 
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Table and Figure Legends 
Table 1. Characteristics of the participants. 
The characteristics of the individuals involved in the study from whom samples of 
breast tissue and blood were taken.  Healthy individuals were matched to the cancer 
patients by age, ethnicity, BMI, menopausal status and familial history of cancer.   
The ages and BMIs are the means of each category.  Post-menopausal status 
includes patients who were surgically post-menopausal, such as following 
hysterectomy.  Familial history of cancer refers to primary and secondary history.  For 
one healthy individual, the familial history was not known. BMI: body mass index. 
 
Table 2. Correlations between DNA methylation of imprinted genes and tumor 
pathology. 
Correlations between aberrant methylation of nine imprinted genes and the tumor 
and patient characteristics were identified using the Pearson correlation (age at 
diagnosis) and ANOVA (tumor stage, receptor status and familial history of cancer).  
For the frequently altered methylation group (FAM, tumors with more than three 
aberrantly methylated imprinted regions), Fisher’s exact test was used to identify 
associations with tumor stage, receptor status and familial history, while a t-test or 
Wilcoxon rank sum test was used to identify associations with age at diagnosis.  P 
values are provided with rho values below where appropriate.  Statistically significant 
(p < 0.05) associations are highlighted in bold.  Down-arrows () indicate reduced 
levels of methylation with expression of the estrogen or progesterone receptor.  For 
the FAM grouping, minus symbols (-) indicate that aberrant methylation is associated 
with negative status of the receptor. 
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Figure 1. DNA Methylation at nine imprinted regions in breast tissue from patients 
and healthy individuals. 
Measured methylation values in breast tissue for DIRAS3 DMR (A), GRB10 ICR (B), 
H19 ICR (C), IGF2 DMR0 (D), IGF2 DMR2 (E), KvDMR (F), MEST ICR (G), PEG3 
DMR (H) and SNRPN/SNURF ICR (I) in healthy individuals and patients with benign 
breast disease and invasive cancer.  Boxes correspond to the median and 
interquartile range, and the whiskers to the full range of measured values. 
Statistically significant differences are indicated (Mann-Whitney U Test; * = p < 0.05; 
** = p <0.01; *** = p < 0.0005; **** = p < 0.0001). 
 
Figure  2. Variation in DNA methylation in breast tissue and blood. 
(A) Mean deviation from the measured median value in normal breast tissue or blood 
from healthy individuals for each of the nine imprinted regions. Results are from 
patients with invasive cancer (), benign breast disease (x) and healthy individuals 
(−).  (B) Change in mean deviation from median methylation values measured in 
normal tissue and blood, relative to values observed in normal breast tissue and 
blood from healthy individuals.  Results for cancer patients from the unadjusted () 
and adjusted () models, and from patients with benign breast disease in the 
unadjusted (x) and adjusted (+) models. 
 
Figure 3. DNA methylation at LINE-1 elements in benign breast disease tissue and 
breast tumors. 
Results are displayed in relation to the FAM status of the tumors (A) and by 
expression of the estrogen receptor (ER) (B).  Boxes correspond to the median and 
interquartile range, and the whiskers to the full range of measured values. 
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Statistically significant differences are indicated (Mann-Whitney U Test; * = p < 0.05; 
** = p <0.01; *** = p < 0.0005; **** = p < 0.0001). 
 
Figure 4. Expression of imprinted genes relative to DNA methylation status. 
Allelic-expression of PEG3 (A), MEST (B) IGF2 relative to DMR0 (C) and DMR2 (D), 
H19 (E) and GRB10 (F).  For each patient, DNA methylation values () and allelic 
expression (bar graph) are provided.  Expression values correspond to the 
percentage of transcripts originating from the more transcribed allele. 
 
Supplementary Table 1. Pathology and receptor status for the cancer patients. 
The AJCC stage and status of the estrogen (ER), progesterone (PR) and HER2 
receptors for each of the 38 cancer patients from whom blood and tumor tissue was 
taken.  The pathology and HER2 status were not known for two patients.  Mammary 
tissue was collected from patients undergoing medical procedures and immediately 
stored on ice for analysis to be performed by a licensed pathologist.  Excess tissue 
was frozen for research purposes.   
 
Supplementary Table 2. Primers used for methylation and expression analysis. 
For each DMR analyzed, the sequences for the forward and reverse primers (PCR) 
and the sequencing primer (pyrosequencing) are provided.  For H19 ICR, the forward 
primer was also used as the sequencing primer, while for IGF2 DMR0 two 
sequencing primers were used with the same PCR product.  DNA methylation at 
LINE-1 elements was analyzed using the PyroMark Q24 CpG LINE-1 assay 
(Qiagen).  Assays were validated by running a scale of 0%, 20%, 40%, 60%, 80% 
and 100% methylated DNA.  Stocks of 0% and 100% methylated DNA were created 
by whole-genome amplification using the RepliG kit (Qiagen) and treatment with MssI 
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(New England Biolabs, Ipswich, USA) respectively, with the two mixed proportionally 
to create the others.  Standards were bisulfite-converted in quadruplicate and the 
correlation in results calculated (r2>0.97).  The SNPs used to identify informative 
patients for analysis of allele-specific expression are provided along with the gene 
name.  
 
Supplementary Table 3. DNA Methylation at nine imprinted regions in blood and 
breast tissue from healthy individuals and patients. 
For each individual, values were calculated from two separate bisulfite-converted 
DNA replicates.  The median and the range in mean values for each subgrouping is 
provided for each of the nine imprinted regions analyzed, along with the number of 
aberrantly methylated samples (hypomethylated / normally methylated / 
hypermethylated).  We have previously reported raw methylation values for GRB10 
ICR, H19 ICR, IGF2 DMR0 and DMR2, KvDMR and SNPRN/SNURF ICR in benign 
and cancer samples18 and we have reanalyzed this data using values from healthy 
individuals to determine the frequency of aberrant methylation in the disease states.  
 
Supplementary Table 4. Modeling of variation in DNA methylation in breast tissue 
and blood. 
(A) The mean deviations from the median methylation levels measured in breast 
tissue or blood from healthy individuals were calculated for healthy individuals, 
patients with benign breast disease, and patients with invasive cancer.  (B) The 
relative fold change in mean deviation was calculated for the benign and invasive 
cancer patients relative to the values measured in healthy individuals.  95% 
confidence intervals are given in brackets.  Asterisks (*) denote statistical 
significance, defined as p<0.05 following Bonferroni correction; †The adjusted model 
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was adjusted for the age, BMI category (‘normal’, ‘overweight’, and ‘obese’), 
menopausal status and familial history of cancer of the individuals.  
 
Supplementary Table 5: Gene expression by hormone receptor status 
Gene expression microarray data from 302 breast tumor samples.  Fold-change in 
expression  (positive versus negative) and statistical significance are provided for ten 
genes (n/s = not significant).  H19 was not present on the microarray.  Of the 302 
tumors, 199 were ER-positive and 103 were ER-negative, while 153 were PR-
positive and 149 PR-negative. 
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Table 1: Characteristics of the participants 
 
 Healthy  Benign breast disease Invasive cancer 
Number of participants 36 30 38 
Age at diagnosis 50.3 47.5 51.5 
Ethnicity (%) 
White 29 (80.6) 21 (70.0) 28 (73.7) 
African-American 7 (19.4) 5 (16.7) 7 (18.4) 
Other 0 (0.0) 4 (13.3) 3 (7.9) 
BMI 28.0 25.2 28.5 
Menopausal 
status (%) 
Pre- 21 (58.3) 20 (66.7) 19 (50.0) 
Post- 15 (41.7) 10 (33.3) 19 (50.0) 
Familial history of cancer (%) 17 (48.6) 11 (36.7) 18 (47.4) 
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Table 2: Correlations between DNA methylation of imprinted genes and tumor pathology 
 
Imprinting 
regions 
Age at diagnosis 
(rho values) 
Tumor 
stage 
ER PR ER/PR HER2 
Familial 
history 
DIRAS3 DMR 0.88 (-0.04) 0.85 0.20 0.36 0.44 0.53 0.55 
GRB10 ICR 0.96 (<0.01) 0.06 0.09 0.45 0.21 0.16 0.20 
H19 ICR 0.39 (-0.16) 0.29 0.67 0.52 0.45 0.57 0.89 
IGF2 DMR0 0.18 (-0.28) 0.15     0.04  0.98      0.02  0.22 0.23 
IGF2 DMR2 0.49 (-0.15) 0.08 0.96 0.65 0.82 0.70 0.32 
KvDMR 0.45 (-0.15) 0.24 0.70 0.31 0.59 0.33 0.38 
MEST ICR 0.94 (-0.01) 0.58 0.23      0.03  0.10 0.40 0.42 
PEG3 DMR 0.33 (-0.18) 0.71    <0.01       0.02       0.01  0.99 0.66 
SNRPN ICR 0.58 (0.12) 0.89 0.89 0.46 0.56 0.61 0.66 
FAM 0.91 0.15    0.02  -    0.02  -     0.02  - 0.32 0.28 
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Figure 1. DNA Methylation at nine imprinted regions in breast tissue from patients 
and healthy individuals. 
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Figure  2. Variation in DNA methylation in breast tissue and blood. 
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Figure 3. DNA methylation at LINE-1 elements in benign breast disease tissue and breast tumors. 
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Figure 4. Expression of imprinted genes relative to DNA methylation status 
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Supplementary Table 1: Pathology and receptor status for the cancer patients 
Tumor Pathology subtype 
AJCC 
stage 
ER PR HER2 
1 IDCA I Neg Neg Pos 
2 IDCA I Pos Pos Neg 
3 IDCA I Neg Neg Neg 
4 IDCA I Pos Neg Pos 
5 IDCA I Pos Pos Neg 
6 IDCA I Pos Pos Pos 
7 IDCA I Neg Neg Neg 
8 IDCA I Pos Pos Neg 
9 IDCA I Neg Neg Neg 
10 IDCA I Pos Pos Neg 
11 IDCA I Pos Neg Neg 
12 IDCA I Pos Pos Neg 
13 IDCA I Pos Pos Pos 
14 IDCA I Pos Pos Pos 
15 IDCA IIA Neg Neg Neg 
16 Mixed ductal and lobular IIA Pos Pos Neg 
17 IDCA IIA Pos Pos Neg 
18 IDCA IIA Neg Neg Neg 
19 IDCA IIA Pos Neg Neg 
20 Apocrine IIA Neg Neg Pos 
21 IDCA IIA Neg Neg Pos 
22 IDCA IIA Pos Neg Neg 
23 Carcinoma with osteoclast giant cells IIA Pos Pos Neg 
24 IDCA IIA Pos Pos Neg 
25 IDCA IIA Pos Pos Neg 
26 IDCA IIA Pos Neg Neg 
27 IDCA IIA Pos Neg Pos 
28 IDCA IIA Pos Pos Neg 
29 IDCA IIA Neg Neg Neg 
30 IDCA IIB Pos Pos Neg 
31 IDCA IIB Pos Pos Neg 
32 IDCA IIB Pos Pos Neg 
33 IDCA IIB Neg Neg Neg 
34 IDCA IIB Pos Pos Neg 
35 - IIB Neg Neg - 
36 Mixed ductal and lobular IIB Pos Neg Neg 
37 IDCA IIIA Pos Neg Neg 
38 IDCA IV Pos Neg Pos 
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Supplementary Table 2: Primers used for methylation and expression analysis 
Analysis Gene / region Primer Sequence (5’ – 3’) 
M
e
th
y
la
ti
o
n
 
DIRAS3 DMR 
Forward AGTTGGATAGGTTTTTGTTGGTAAAG 
Reverse CAACTAAACACCCCAAAAACTC 
Sequencing GATTAGTTTTTAGATTGTTGTAGAT 
GRB10 ICR 
Forward GAGGAGGTAGTGGAGGGAATAAG 
Reverse ATCCCAAAACCAAACCCATAT 
Sequencing TGGGTAGTAGAGGGT 
H19 ICR 
Forward TGAGTGTTTTATTTTTAGATGATTTT 
Reverse ACAATACAAACTCACACATCACAAC 
Sequencing TGAGTGTTTTATTTTTAGATGATTTT 
IGF2 DMR0 
Forward TGAGGATGGGTTTTTGTTTGGTAT 
Reverse TCCTCGATCCACCCAAAATAATAT 
Sequencing 1 GGGGTGGAGGGTGTA 
Sequencing 2 AAAAGTTATTGGATATATAGT 
IGF2 DMR2 
Forward GGTTAGGAGGAGGTTGTAGG 
Reverse CCAAAACAACTTCCCCAAATAC 
Sequencing GGGTGGGTAGAGTAA 
KvDMR 
Forward ATTTTAGGGGGTGAGTGGTA 
Reverse ACTTTTATAACCCAAACTTTTATCCC 
Sequencing AGGTTATTTATTTGGTAAAGG 
MEST ICR 
Forward TAGTTTGGTGGTGGGTTTAATAGA 
Reverse ACCCCTAAATACCCCAACTCTT 
Sequencing AGTTTAGGGAGTATAGGGTT 
PEG3 DMR 
Forward  ATTTAGGTGTAGAAGTTTGGGTAGT 
Reverse  ACTCACCTCACCTCAATACT 
Sequencing  GTTTATTTTGGGTTGGT 
SNRPN/SNURF ICR 
Forward GGGAGGGAGTTGGGATTTTTG 
Reverse AAACCACCCACACAACTAACCTTACCC 
Sequencing AGTTGGGATTTTTGTATTG 
A
ll
e
le
-s
p
e
c
if
ic
 e
x
p
re
s
s
io
n
 
DIRAS3 rs61736596 
Forward GGAGGTGGCCCTGAATGA 
Reverse TGCACATTCACATCGGTCTTG 
Sequencing CGATGGAGTGGAATTG 
GRB10 rs1800504 
Forward TCCCTGGAGAGCCTGTACTCG 
Reverse GGGAGCGCTGCACCCTCT  
Sequencing GCTGCACCCTCTGCC 
H19 rs3741219 Taqman Assay ID C_274925_10 
H19 rs2839698 Taqman Assay ID C_2603701_10 
IGF2 rs2585 Taqman Assay ID C_8692758_10 
IGF2 rs3802971 Taqman Assay ID C_31456526_10 
MEST rs1050582 
Forward-Genotyping 
Forward-Expression 
Reverse 
CATGGGCTTCTTGAATGCATA 
AGCTCTTGCCTCTGTAACTATCCC 
GGCATTTCTTCCTAAGTGGAATAC 
TCCTAAGTGGAATACACAAC Sequencing 
PEG3 rs18600565 
Forward 
Reverse 
Sequencing 
ATTTGTTGGGCCTCGGAAG 
CTCTCTTCTGTTCCGGGTCAT 
ACAACAACAGTGACGTG 
PEG3 rs33931963 
Forward TTGGTTTACTGGGCCCTGCT 
Reverse AAAAGGCGTTCACCATTAGCTCT 
Sequencing TCCCACTAAGGAAAATG 
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Supplementary Table 3: DNA methylation at nine imprinted regions in blood and breast tissue from healthy individuals and patients 
 
 
DIRAS3 
DMR 
GRB10 ICR H19 ICR IGF2 DMR0 IGF2 DMR2 KvDMR MEST ICR PEG3 DMR 
SNRPN/ 
SNURF ICR 
Breast 
tissue 
Normal 
Median 49.1 44.4 43.7 62.4 40.4 40.6 44.3 47.5 36.8 
Range 41.8 - 52.4 31.7 - 46.5 40.6 - 51.6 47.3 - 71.9 23.4 - 49.3 35.8 - 44.4 37.0 - 51.8 44.4 - 53.0 33.8 - 38.1 
Hypo/hyper 0 / 34 / 0 0 / 36 / 0 0 / 33 / 0 0 / 35 / 1 3 / 33 / 0 0 / 28 / 0 0 / 36 / 0 0 / 36 / 0 0 / 36 / 0 
Benign 
Median 50.3 49.0 46.8 55.4 31.1 44.4 45.8 52.9 42.6 
Range 43.5 - 57.0 44.8 - 55.9 32.9 - 53.4 42.0 - 66.3 20.8 - 61.2 32.5 - 53.9 39.2 - 60.4 39.0 - 63.2 32.9 - 51.9 
Hypo/hyper 0 / 21 / 0 0 / 29 / 0 0 / 27 / 0 0 / 28 / 0 12 / 14 / 0 0 / 22 / 0 0 / 26 / 0 0 / 26 / 0 0 / 26 / 0 
Cancer 
Median 46.5 48.1 42.1 42.6 27.4 43.3 52.2 54.8 41.1 
Range 12.1 - 78.0 8.3 - 79.0 17.1 - 77.7 13.5 - 63.5 12.8 - 65.1 23.9 - 65.0 24.2 - 88.4 24.4 - 85.9 26.2 - 61.7 
Hypo/hyper 7 / 14 / 1 7 / 27 / 1 5 / 27 / 1 9 / 15 / 0 13 / 9 / 0 2 / 24 / 0 2 / 26 / 4 1 / 26 / 6 1 / 23 / 0 
Blood 
Normal 
Median 49.8 46.0 44.4 48,1 48.2 44.7 45.6 49.3 39.1 
Range 34.1 - 52.0 44.1 - 48.2 42.2 - 51.5 36.6 - 54.4 40.8 - 65.0 40.3 - 47.4 41.6 - 50.5 45.9 - 56.6 35.6 - 41.1 
Hypo/hyper 0 / 32 / 0 0 / 32 / 0 0 / 31 / 0 0 / 34 / 0 0 / 33 / 0 0 / 32 / 0 0 / 34 / 0 0 / 33 / 0 0 / 33 / 0 
Benign 
Median 48.7 47.4 46.2 46.6 51.7 45.6 47.7 53.5 41.1 
Range 44.3 - 59.6 44.4 - 49.6 42.7 - 49.4 39.5 - 56.8 43.5 - 61.9 39.3 - 48.6 40.0 - 54.3 50.3 - 58.1 36.5 - 43.3 
Hypo/hyper 0 / 22 / 0 0 / 30 / 0 0 / 26 / 0 0 / 29 / 0 0 / 32 / 0 0 / 29 / 0 0 / 26 / 0 0 / 26 / 0 0 / 29 / 0 
Cancer 
Median 50.3 47.6 46.2 48.3 51.0 46.0 46.6 53.6 41.4 
Range 46.2 - 57.0 43.9 - 50.2 43.8 - 50.2 35.7 - 58.4 38.2 - 69.5 40.8 - 53.8 38.2 - 53.4 48.6 - 59.6 38.0 - 44.7 
Hypo/hyper 0 / 20 / 0 0 / 35 / 0 0 / 32 / 0 0 / 37 / 0 0 / 37 / 0 0 / 31 / 0 0 / 31 / 0 0 / 31 / 0 0 / 33 / 0 
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Supplementary Table 4: Modeling of variation in DNA methylation in breast tissue and blood 
 
 
 
(A) Mean deviation from 
median methylation 
(B) Relative fold change in mean deviation from median methylation level (95% CI) 
 
Imprinted 
region 
Median 
methylation 
level in healthy 
individuals (%)  
Healthy 
(n=36) 
Benign 
(n=29 
and 32) 
Invasive 
(n=38) 
Unadjusted Model Adjusted Model † 
Benign vs. Healthy Invasive vs. Healthy Benign vs. Healthy Invasive vs. Healthy 
Breast 
tissue 
DIRAS3 DMR 49.1 1.7 2.5 16.0 1.5 (0.9, 2.5) 9.7* (5.9, 15.8) 1.3 (0.8, 2.2) 9.6* (5.7, 16.2) 
GRB10 ICR 44.4 1.2 5.2 11.0 4.5* (2.3, 8.9) 9.6* (5.0, 18.4) 5.7* (3.3, 9.8) 9.9* (5.9, 16.5) 
H19 ICR 43.7 1.5 4.0 10.3 2.7* (1.7, 4.3) 7.1* (4.5, 11.2) 3.0* (1.9, 4.7) 6.6* (4.2, 10.2) 
IGF2 DMR0 62.4 4.2 7.6 23.0 1.8* (1.3, 2.6) 5.5* (3.7, 8.0) 1.8 (1.2, 2.7) 5.2* (3.5, 7.7) 
IGF2 DMR2 40.4 5.5 11.2 14.4 2.1* (1.5, 2.9) 2.6* (1.8, 3.8) 2.0* (1.4, 2.8) 2.6* (1.7, 3.7) 
KvDMR 40.6 1.5 4.3 7.2 3.0* (1.9, 4.7) 4.9* (3.0, 8.2) 3.1* (1.7, 5.2) 5.1* (2.9, 9.0) 
MEST ICR 44.3 2.0 4.3 13.5 2.1* (1.3, 3.4) 6.7* (4.6, 9.8) 1.9 (1.2, 3.0) 7.3* (4.9, 11.0) 
PEG3 DMR 47.5 1.5 5.9 12.5 4.0* (2.6, 5.9) 8.4* (5.6, 12.7) 4.4* (2.9, 6.7) 9.0* (5.9, 13.8) 
SNRPN ICR 36.8 0.9 6.7 6.6 7.5* (5.3, 10.7) 7.4* (4.8, 11.4) 7.9* (5.5, 11.3) 7.3* (4.7, 11.5) 
Blood 
DIRAS3 DMR 49.8 1.6 3.0 2.0 1.9 (0.9, 4.2) 1.3 (0.6, 2.8) 1.8 (1.1, 3.1) 1.1 (0.7, 2.0) 
GRB10 ICR 46.0 0.7 1.5 1.7 2.2* (1.5, 3.2) 2.5* (1.8, 3.6) 2.6* (1.8, 3.7) 2.8* (2.0, 4.1) 
H19 ICR 44.4 1.2 2.0 1.9 1.7 (1.0, 2.7) 1.6 (1.0, 2.5) 1.8 (1.0, 3.1) 1.6 (1.0, 2.7) 
IGF2 DMR0 48.1 3.2 4.0 4.2 1.3 (0.9, 1.8) 1.3 (0.9, 1.9) 1.3 (0.9, 1.9) 1.3 (0.9, 1.9) 
IGF2 DMR2 48.2 2.7 4.7 5.1 1.7 (1.1, 2.9) 1.9 (1.1, 3.2) 1.9 (1.2, 3.0) 2.5* (1.5, 4.1) 
KvDMR 44.7 1.1 1.8 2.1 1.6 (1.1, 2.5) 1.9* (1.3, 2.9) 1.8 (1.2, 2.7) 1.8 (1.2, 3.0 
MEST ICR 45.6 1.6 3.0 2.6 1.9* (1.3, 2.8) 1.7 (1.1, 2.5) 1.8* (1.2, 2.7) 1.5 (1.0, 2.4) 
PEG3 DMR 49.3 1.5 4.3 4.4 2.8* (1.7, 4.7) 2.9* (1.8, 4.7) 3.0* (1.8, 5.1) 2.8* (1.7, 4.6) 
SNRPN ICR 36.8 0.9 2.0 2.5 2.3* (1.5, 3.4) 2.8* (1.9, 4.0) 2.5* (1.8, 3.7) 3.4* (2.4, 4.7) 
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Supplementary Table 5: Gene expression by hormone receptor status 
 
Gene 
ER+ vs ER- PR+ vs PR- 
Fold-change Significance Fold-change Significance 
DIRAS3 1.1 n/s 1.2 n/s 
DNMT1 -1.1 n/s -1.1 n/s 
DNMT3A -1.3 n/s -1.1 n/s 
DNMT3B -1.6 n/s -1.3 n/s 
GRB10 -1.4 p = 1.7-10 1.0 n/s 
IGF2 1.9 p = 6.0-7 1.4 n/s 
KCNQ1 1.1 n/s 1.0 n/s 
MEST 1.0 n/s 1.1 n/s 
PEG3 1.2 n/s 1.1 n/s 
SNRPN 1.0 n/s 1.0 n/s 
 
 
